The FDA has cleared the way for ViaCyte's application to start a Phase I/II clinical trial of VC-01 for the treatment of type 1 diabetes. Insulin-producing cells derived from stem cells will be implanted inside a semi-permeable pouch. The trial is funded by the California Institute for Regenerative Medicine.

Related Summaries